Dacarbazine (CAS 4342-03-4)/Antitumor

Dacarbazine (CAS 4342-03-4) is a high-purity pharmaceutical API classified as a potent alkylating agent, featuring an imidazole-carboxamide molecular structure that exerts cytotoxic effects via bioactivation in the liver. Unlike direct-acting chemotherapeutics, it is converted to its active form (MTIC) to alkylate DNA—forming cross-links and inducing strand breaks that disrupt cancer cell replication and trigger apoptosis. This classic anticancer API exhibits broad-spectrum activity, with well-established efficacy in treating hematologic and solid tumors.

It caters to the core needs of oncology drug manufacturers, chemotherapy formulation developers, and clinical supply chains. Widely applied in developing treatments for malignant melanoma, Hodgkin lymphoma, and soft tissue sarcoma, it aligns with the demand for reliable, first-line chemotherapy agents. Produced under strict GMP standards, each batch undergoes rigorous purity and stability testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing time-tested, broad-spectrum anticancer raw materials, this Dacarbazine API serves as a critical component for advancing chemotherapy medication development.